trial

Evaluation of Effectiveness of Risperdal® Consta® Compared to Abilify® Over a Two-year Period in Patients With Schizophrenia

NCTId NCT00299702
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Completed
Enrollment 355 (actual)
Sponsored by Johnson & Johnson
Primary completion 2009-01
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Completed
Enrollment
355 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
None
Start
2006-02
Primary completion
2009-01
Eligibility
ALL · 18 Years

Interventions & indications

Drugs
AripiprazoleRisperidal Consta

Sponsors

Johnson & JohnsonLead Sponsor
Janssen, L.P. - Investigator Initiated Studies ProgramCollaborator

Sites

0 total

Facts & assertions

4 sourced
Enrollment
355
Phase
PHASE4
Primary Completion Date
2009-01
Status
COMPLETED
relationships
The graph out of here
drug
Aripiprazole
drug
Risperidal Consta
drug
lead_sponsor
Johnson & Johnson
company
collaborator
Janssen, L.P. - Investigator Initiated Studies Program
company
indication
Psychotic Disorders
indication
Psychotic Disorders
indication
Schizophrenia
indication